Telescope Innovations's ROE % for the quarter that ended in May. 2026 was -137.47%. Telescope Innovations's PB Ratio for the quarter that ended in May. 2026 was 14.52.
Telescope Innovations's ROE % Adjusted to Book Value for the quarter that ended in May. 2026 was -9.47%.
Telescope Innovations ROE % Adjusted to Book Value Related Terms
Telescope Innovations ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Telescope Innovations's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telescope Innovations ROE % Adjusted to Book Value Chart
TELIF vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Telescope Innovations's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -9.47% mean?
Telescope Innovations (TELIF) has a ROE % Adjusted to Book Value of -9.47% as of May. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Telescope Innovations and its competitors.
Is Telescope Innovations' ROE % Adjusted to Book Value too high?
Telescope Innovations' current ROE % Adjusted to Book Value is -9.47%. Overall, Telescope Innovations has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' ROE % Adjusted to Book Value compare to VRTX and REGN?
Telescope Innovations' ROE % Adjusted to Book Value of -9.47% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Telescope Innovations and its competitors. Telescope Innovations's current ROE % Adjusted to Book Value is -9.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.39, compared to a current price of $0.53 — trading 36.4% above its estimated fair value. The current ROE % Adjusted to Book Value is -9.47%. Telescope Innovations' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current ROE % Adjusted to Book Value is -9.47% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be overvalued.
The current stock price of $0.53 is trading 36.4% above its estimated GF Value™ of $0.39.
GuruFocus considers Telescope Innovations to be Significantly Overvalued.
Key valuation signals for TELIF:
ROE % Adjusted to Book Value: -9.47%
GF Value™: $0.39 vs. price of $0.53 (36.4% above fair value)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
33GF Score
Get the complete analysis for TELIF
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
